Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fibrosis by Deschamp, Ashley R et al.
SAGE Open Medicine
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  
Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, 
reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open 
Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
https://doi.org/10.1177/2050312117736694
SAGE Open Medicine
Volume 5: 1 –6
© The Author(s) 2017
Reprints and permissions: 
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1 77/205 3121 7 366
journals.sagepub.com/home/smo
Introduction
A significant contributor to morbidity and mortality in 
patients with cystic fibrosis (CF) is chronic lung infection 
with Pseudomonas aeruginosa. Recurrent infection with 
P. aeruginosa induces a state of chronic inflammation 
which in turn leads to irreversible pulmonary damage and 
declining lung function.1 Antibiotics have long been used 
as a principal component of treatment for pulmonary exac-
erbations in CF. Historically, aminoglycosides were dosed 
in multiple daily doses. However, aminoglycosides exert 
Safety of intravenous tobramycin  
in combination with a variety of  
anti-pseudomonal antibiotics in  
children with cystic fibrosis
Ashley R Deschamp1, Rebecca S Pettit2,  
Jennifer A Donaldson2, James E Slaven3 and Stephanie D Davis2
Abstract
Objectives: Previous studies have examined renal safety of once daily intravenous tobramycin in individuals with cystic 
fibrosis. This has been mainly in combination with ceftazidime in an adolescent or adult population. In this report, we 
describe our institutional experience of once daily intravenous tobramycin in combination with a variety of second anti-
pseudomonal antibiotics in children with cystic fibrosis.
Methods: We present a retrospective review including children with cystic fibrosis, who were admitted for a pulmonary 
exacerbation from January 2009 to December 2011, and treated using intravenous tobramycin. A literature review of once 
daily intravenous aminoglycoside dosing in cystic fibrosis was performed to compare our results to existing literature.
Results: A total of 35 subjects were divided into once daily dosing (n = 20) versus multiple daily dosing (n = 15) groups. Mean 
age was 11.3 years (± 5.7) for the once daily dosing group and 13.1 years (± 4.4) for the multiple daily dosing group (p = 0.34). 
All subjects had normal baseline serum creatinine at admission (once daily dosing 0.49 ± 0.14 mg/dL vs multiple daily dosing 
0.62 ± 0.23 mg/dL, p = 0.07). All subjects received intravenous tobramycin, and most received piperacillin-tazobactam as their 
second anti-pseudomonal antibiotic (once daily dosing 45% and multiple daily dosing 40%). There was no significant change 
in serum creatinine in either group during antibiotic treatment (once daily dosing 0.08 ± 0.12 mg/dL vs. multiple daily dosing 
0.06 ± 0.10 mg/dL, p = 0.43). All subjects had significant improvement in lung function following intravenous antibiotic therapy.
Conclusion: We show that both once daily dosing and multiple daily dosing of intravenous tobramycin in combination with 
a variety of second anti-pseudomonal antibiotics were safe in terms of nephrotoxicity in children with cystic fibrosis. These 
findings are important given existing literature mainly examines once daily tobramycin in combination with ceftazidime, a 
cephalosporin, and the majority of our patients were on tobramycin with piperacillin-tazobactam, an extended spectrum 
penicillin plus beta-lactam. This contributes new information not previously examined in a pediatric cystic fibrosis population.
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concentration-dependent killing. The once daily dosing 
(ODD) interval achieves a high maximal concentration to 
minimum inhibitory concentration (Cmax/MIC) ratio; 
thereby, enhancing killing of P. aeruginosa2 compared to 
the traditional multiple daily dosing (MDD) regimen. 
Furthermore, this regimen allows trough concentrations to 
fall below detectable limits and provides a drug free inter-
val which may reduce the risk of nephrotoxicity.
However, aminoglycoside therapy is still associated with 
adverse side effects; thereby, leading researchers to investi-
gate the safest and most efficacious dosing regimen for these 
drugs.3 Studies examining the safety of once daily IV amino-
glycoside dosing report it to be safe and effective in treating 
CF exacerbations due to P. aeruginosa.4 The Tobramycin 
Once-Daily Prescribing in Cystic Fibrosis (TOPIC) study, a 
large randomized controlled trial, specifically determined 
ODD of tobramycin in combination with ceftazidime was 
equally efficacious compared to MDD and also possibly less 
nephrotoxic in children with CF.5 Cystic Fibrosis Foundation 
(CFF) guidelines recommend double antibiotic coverage for 
treatment of pulmonary exacerbations secondary to P. aer-
uginosa, with one of these antibiotics usually being an ami-
noglycoside.6 Also, more recent CFF guidelines recommend 
ODD of IV aminoglycosides when used for treatment of a 
pulmonary exacerbation.7 A survey found that 61% of CFF-
Accredited Care centers have adopted ODD of IV tobramy-
cin.8 However, minimal data exist examining the effects 
once daily versus multiple daily tobramycin dosing in chil-
dren with CF when combined with a variety of other anti-
pseudomonal antibiotics, other than ceftazidime. In this 
report, we present our institutional experience with ODD of 
IV tobramycin in combination with a variety of second anti-
pseudomonal agents.
Materials and methods
Retrospective review
Approval for this study was obtained from the Indiana 
University Institutional Review Board. This retrospective 
chart review included randomly selected participants with 
CF ≤ 18 years of age, with a CF-related pulmonary exacerba-
tion, admitted to the hospital for IV antibiotic therapy with 
tobramycin from January 2009 to December 2011. The diag-
nosis of a pulmonary exacerbation was made by the attend-
ing pulmonary physician based on clinical judgment of 
symptoms such as cough, shortness of breath, changes in 
sputum, and/or weight loss. Antibiotics were chosen by the 
pulmonary physician and CF pharmacist. Those subjects 
receiving IV vancomycin were excluded due to the potential 
for adverse renal effects from vancomycin. Chronic inhaled 
aminoglycosides were not continued during the IV antibiotic 
course.
Nephrotoxicity was defined using the pediatric Risk, 
Failure, Loss, End stage renal disease (pRIFLE) criteria with 
an increase of ≥0.3 mg/dL or ≥1.5-fold increase in the creati-
nine level from baseline being considered significant.9 In 
order to detect a change in serum creatinine (SCr) of 0.3 mg/
dL, a sample size of 5 in each group were required with a 
power of 0.8. Estimated glomerular filtration rate (eGFR) 
was calculated using the Schwartz equation.10 We reviewed 
100 charts, 35 subjects meeting the above criteria were 
selected. Demographic and clinical data collected included 
duration of treatment, anti-pseudomonal agents used, base-
line and peak SCr concentrations, tobramycin dose, and 
spirometry at the beginning and end of antibiotic treatment. 
The duration of antibiotic therapy was determined by the 
treating pulmonary physician.
Review of the literature
PubMed and MEDLINE databases were queried for “once 
daily aminoglycosides AND cystic fibrosis” from January 
1994 to January 2015. Only studies in English language 
were included. A total of 62 articles were identified. There 
were 21 clinical trials and 14 review articles, with 3 of those 
being Cochrane reviews. Articles that addressed once daily 
aminoglycoside dosing and combinations with a second anti-
pseudomonal agent were included in the review. These find-
ings are presented in the discussion.
Results
Patient characteristics
A total of 35 subjects were included for analysis. They were 
divided into ODD and MDD groups based on the frequency 
of IV tobramycin administration. The ODD group received 
IV tobramycin every 24 h. The MDD group received IV 
tobramycin every 8 h or every 12 h. Table 1 illustrates their 
demographic and clinical characteristics. The average age 
was 11.3 ± 5.7 years in the ODD group and 13.1 ± 4.4 years 
in the MDD group (p = 0.34). In the ODD group, 45% (n = 9) 
were male. In the MDD group, 60% (n = 9) were male 
(p = 0.49). All participants were Caucasian. The mean body 
mass index (BMI) was 17.3 ± 2.4 in the ODD group and 
17.2 ± 2.8 in the MDD group (p = 1.00). Participants receiv-
ing vancomycin were excluded; however, those receiving 
nonsteroidal anti-inflammatory drugs (NSAIDS) were not 
excluded. There were only four subjects on NSAIDS, all in 
the ODD group. Only one subject was on inhaled antibiotics 
during the course of IV therapy, and this participant was on 
colistin. There were similar rates of CF-related diabetes 
(CFRD) and CF liver disease. Indicators of renal function 
used were SCr and eGFR. Baseline SCr was normal in both 
groups and did not differ significantly between the groups 
(ODD 0.49 ± 0.14 mg/dL vs MDD 0.62 ± 0.23 mg/dL, 
p = 0.07). GFR was estimated (eGFR) using the Schwartz 
equation10 and was normal in both groups (114.5 ± 24.8 mL/
min/1.73 m2 in the ODD group and 99.0 ± 44.4 mL/
min/1.73 m2 in the MDD group, p = 0.24). In order to have an 
estimate of hydration status, blood urea nitrogen to creati-
nine (BUN/Cr) ratio was used as this has been shown to be 
associated with increasing fluid deficit.11 The baseline BUN/
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Cr ratio was 18.3 ± 8.6 in the ODD group and 18.5 ± 10.4 in 
the MDD dosing group (p = 0.96), both in the normal range 
and not significantly different.
Antibiotics and outcomes
All subjects were administered IV tobramycin. Most sub-
jects were on piperacillin-tazobactam as their second anti-
pseudomonal antibiotic (45%, n = 9 in the ODD group and 
40%, n = 6 in the MDD group, p = 1.00). The breakdown of 
anti-pseudomonal agents is displayed in Table 2. Note, a few 
subjects in the ODD group received more than one antibiotic 
agent duringtheir treatment course in addition to tobramycin, 
and one subject in the MDD group was missing data. Table 3 
shows study outcomes including days of inpatient and outpa-
tient IV aminoglycosides, area under the curve (AUC), and 
change in SCr. AUC was calculated to measure aminoglyco-
side exposure between the two groups. There was no signifi-
cant difference in AUC between the ODD and MDD groups 
(1035 ± 609 vs 1045 ± 517, respectively, p = 0.96). The dura-
tion of IV aminoglycoside therapy did not significantly dif-
fer between the two groups (ODD inpatient 10.7 ± 5.5 days 
vs MDD inpatient 9.4 ± 4.8 days, p = 0.49). The duration of 
therapy outpatient for the ODD group was 10.9 ± 3.4 days 
versus that for the MDD group which was 8.7 ± 4.8 days 
(p = 0.26). A dosing adjustment was made in 40% (n = 8) of 
participants in the ODD group and 53% (n = 8) in the MDD 
group based on measured AUC during their antibiotic course. 
Mean baseline creatinine was 0.49 ± 0.14 mg/dL in the ODD 
group and 0.62 ± 0.23 mg/dL in the MDD group without sig-
nificant difference between the groups (p = 0.07). The mean 
change in creatinine was 0.08 ± 0.12 mg/dL in the ODD 
group and 0.06 ± 0.10 mg/dL in the MDD group (p = 0.43), 
which was not statistically significant between groups and 
not clinically significant based on pRIFLE criteria as noted 
in the methods. Lung function was measured at the start and 
end of IV antibiotic therapy including forced vital capacity 
(FVC), forced expiratory volume in 1 second (FEV1), and 
forced expiratory flow between 25% and 75% of vital capac-
ity (FEF25–75). These values are displayed in Table 4 using 
Table 1. Demographics.
Once daily
dosing (ODD)
(n = 20)
Multiple daily
doses (MDD)
(n = 15)
p-value
Age (years) 11.3 (5.7) 13.1 (4.4) 0.34
Weight (kg) 31.6 (13.4) 37.1 (12.8) 0.23
Height (cm) 131.4 (38.1) 147.4 (18.0) 0.07
BMI 17.3 (2.4) 17.2 (2.8) 1.00
Male 9 (45) 9 (60) 0.50
Caucasian 20 (100) 15 (100) NA
Baseline lab measures
 Cr (mg/dL) 0.49 (0.14) 0.62 (0.23) 0.07
 BUN (mg/dL) 8.7 (4.2) 10.5 (4.4) 0.22
 BUN/Cr ratio 18.3 (8.6) 18.5 (10.4) 0.96
  eGFR (mL/
min/1.73 m2)
114.5 (24.8) 99.0 (44.4) 0.24
Other factors
 CFRD (Y) 4 (20) 5 (33) 0.45
 CF liver disease (Y) 1 (5) 1 (7) 1.00
 NSAIDS (Y) 4 (20) 0 (0) 0.12
BMI: body mass index; BUN: blood urea nitrogen; eGFR: estimated 
glomerular filtration rate; CFRD: cystic fibrosis–related diabetes; CF: 
cystic fibrosis; NSAIDS: nonsteroidal anti-inflammatory drugs.
Table 2. Second anti-pseudomonal antibiotic.
Antibiotic agent Once daily
dosing (ODD)
(n = 20)
Multiple daily 
doses (MDD)
(n = 15)
p-value
Piperacillin-tazobactam 9 (45) 6 (40) 1.00
Cefepime 5 (25) 2 (13) 0.67
Ticarcillin-clavulanate 3 (15) 2 (13) 1.00
Meropenem 4 (20) 2 (13) 0.68
Ceftazidime 0 (0) 1 (7) 0.43
Imipenem 0 (0) 1 (7) 0.43
Cefoxitin 1 (5) 0 (0) 1.00
Ceftriaxone 1 (5) 0 (0) 1.00
Table 3. Study outcomes.
Once daily
dosing (ODD)
(n = 20)
Multiple daily 
doses (MDD)
(n = 15)
p-value
Inpatient IV 
aminoglycoside (days)
10.7 (5.5) 9.4 (4.8) 0.49
Outpatient IV 
aminoglycoside (days)
10.9 (3.4) 8.7 (4.8) 0.26
AUC (inpatient) 1035 (609) 1045 (517) 0.96
Baseline SCr (mg/dL) 0.49 (0.14) 0.62 (0.23) 0.07
Change in SCr (mg/dL) 0.08 (0.12) 0.06 (0.10) 0.43
IV: intravenous; AUC: area under the curve; SCr: serum creatinine.
Table 4. Lung function.
Once daily
dosing (ODD)
(n = 17)
Multiple daily 
doses (MDD)
(n = 15)
p-value
FVC z-score (start) −2.59 (1.62) −2.99 (2.32) 0.57
FVC z-score (end) −1.22 (1.34) −1.84 (2.66) 0.43
FVC z-score (difference) 1.39 (1.31) 1.14 (1.01) 0.61
FEV1 z-score (start) −3.59 (1.52) −4.68 (−2.35) 0.78
FEV1 z-score (end) −2.38 (1.55) −2.55 (2.21) 0.83
FEV1 z-score (difference) 1.24 (1.53) 1.27 (1.15) 0.96
FEF25–75 z-score (start) −3.40 (1.58) −3.89 (2.24) 0.49
FEF25–75 z-score (end) −2.63 (2.10) −2.93 (2.39) 0.74
FEF25–75 z-score 
(difference)
0.91 (1.46) 1.16 (1.13) 0.63
FVC: forced vital capacity; FEV1: forced expiratory volume in 1 sec;
FEF25–75: forced expiratory flow between 25% and 75% of vital capacity.
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z-scores. It shows abnormal lung function (z-score less than 
–1.96) at the start of therapy in both groups and in all lung 
function parameters measured. These all improved with IV 
antibiotic therapy.
Discussion
In our retrospective review, we show a clinically significant 
improvement in lung function without nephrotoxicity in pedi-
atric CF subjects on ODD and MDD of IV tobramycin in 
combination with a variety of second anti-pseudomonal 
agents. Although we only included a small number of sub-
jects, this is an important finding. Based on CFF recommen-
dations for double antibiotic coverage of pulmonary 
exacerbations suspected to be due to P. aeruginosa,6 IV ami-
noglycosides are frequently used in combination with a vari-
ety of second anti-pseudomonal antibiotics. It is therefore 
pertinent to consider the safety and efficacy of these drug 
combinations. Most importantly, we show the safety and effi-
cacy of once daily IV aminoglycosides combined with a sec-
ond anti-pseudomonal agent as this regimen follows the most 
recent CFF treatment recommendations.7
Two clinical trials are published involving once daily IV 
aminoglycosides in children.12,13 The first was a randomized 
clinical trial in 22 CF subjects, mean age 11 years old, com-
paring once daily IV tobramycin dosing to thrice daily dos-
ing, both groups in combination with ceftazidime as the 
second agent. They reported clinical improvement in both 
groups without renal or ototoxicity with no statistically sig-
nificant difference between groups. The authors concluded 
once daily tobramycin combined with ceftazidime was safe 
and effective for treatment of P. aeruginosa exacerbations in 
CF.13 The next study compared the safety and efficacy of 
once daily IV tobramycin monotherapy to conventional 
thrice daily tobramycin coupled with ceftazidime IV for 
acute P. aeruginosa pulmonary exacerbations in CF.12 A total 
of 51 subjects were randomized into two groups, mean age 
16 years old in the conventional treatment group and 14 years 
in the tobramycin monotherapy group. They reported once 
daily tobramycin monotherapy to be as effective and safe as 
conventional thrice daily tobramycin/ceftazidime therapy.12 
Both of these studies demonstrated that once daily IV 
tobramycin is safe and as effective as traditional thrice daily 
dosing without significant differences in safety or efficacy.
Although not specific to CF, a meta-analysis of 24 studies 
examined extended interval aminoglycoside administration 
for children with a variety of conditions, 3 studies involving 
CF subjects. This meta-analysis concluded there were no 
significant difference in the failure rates, primary nephrotox-
icity outcomes, or ototoxicity between ODD and multiple 
daily doses of IV aminoglycosides.14
The largest study to date evaluating once daily amino-
glycoside dosing was the TOPIC study published by Smyth 
and colleagues in 2005. The TOPIC study was a large, 
multi-centered, randomized controlled trial that included 
244 subjects. Of these, 125 were children. Subjects were 
randomized to receive either once daily or multiple daily 
doses of IV tobramycin with ceftazidime. They concluded 
that once daily IV tobramycin had equal efficacy for pul-
monary exacerbations based on pulmonary function testing 
and that the once daily regimen might be less nephrotoxic 
in children.5 The subjects enrolled in this study all received 
ceftazidime as the second anti-pseudomonal agent in com-
bination with tobramycin, and no additional antibiotic 
agents were evaluated in combination with once daily 
tobramycin.
The previously mentioned studies all used clinical end-
points. Another group examined the safety of once daily 
IV tobramycin in 18 subjects with CF using pharmacoki-
netics. Subjects were older, with a mean age of 24.6 years 
and only included two pediatric subjects. They were 
administered IV tobramycin in doses ranging from 7 to 
15 mg/kg/d (mean dose 11.9 mg/kg/d). Peak serum concen-
trations, mean total body clearance, volume of distribu-
tion, and elimination half-life were measured. No 
ototoxicity or nephrotoxicity was observed, and assess-
ments were based on hearing screen and SCr, respectively. 
Using a combination of pharmacokinetic and clinical data, 
they concluded once daily IV tobramycin may be used 
safely to treat pulmonary exacerbations in subjects with 
CF. Investigators did not use a second anti-pseudomonal 
agent to treat subjects in this study.15
In 2012, the most recent Cochrane review regarding 
ODD versus MDD of IV aminoglycosides for CF was pub-
lished.4 They included four studies with a total of 328 sub-
jects that evaluated the efficacy and toxicity of once versus 
thrice daily dosing of IV tobramycin for a pulmonary exac-
erbation in CF. Two of the studies are described above,5,13 
and the results of the other two are as follows. The first of 
these was performed only in adults. A total of 30 subjects 
received once daily IV tobramycin and 19 received thrice 
daily IV tobramycin. The second anti-pseudomonal agents 
included piperacillin, tazocin, aztreonam, azlocillin, mero-
penem, imipenem, or ceftazidime and were selected based 
on sputum cultures and sensitivity results. Both groups 
showed significant improvement in respiratory function as 
measured by pulmonary function testing without clinically 
significant changes in renal function. They concluded these 
were encouraging results, but suggested larger multi-cen-
tered studies to confirm the results.16 The next study was 
designed to determine the efficacy of continuous versus 
thrice daily ceftazidime therapy in CF administered con-
comitantly with once daily IV tobramycin. This study 
included a total of 56 subjects, mean age 14.4 years. They 
concluded both regimens to be efficacious by clinical and 
pulmonary function measures, but did not report creati-
nine.17 Cochrane concluded, based on review of the litera-
ture, that once daily and three-times daily dosing of IV 
aminoglycoside antibiotics appeared to be equally effective 
in the treatment of CF pulmonary exacerbations and based 
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on the TOPIC study that ODD may have less nephrotoxic 
effects in children.4
Although multiple groups have examined the safety and 
efficacy of once daily aminoglycoside dosing compared to 
thrice daily dosing in pulmonary exacerbations in subjects 
with CF, only a small pediatric CF population was repre-
sented. Also, the majority of these studies were performed 
with subjects on only ceftazidime as the second anti-pseu-
domonal agent. The only study that used a wider variety of 
anti-pseudomonal agents was in adults only and authors did 
not clearly specify the number of subjects receiving each 
antibiotic combination. There has been little work published 
showing the safety of once daily IV tobramycin in children 
with CF using additional anti-pseudomonal antibiotics, other 
than ceftazidime. This is an important gap as in clinical prac-
tice, a variety of anti-pseudomonal antibiotics may be used 
based on respiratory cultures and bacterial susceptibilities. In 
our study, we used an exclusively pediatric population and 
showed the use of multiple anti-pseudomonal agents in com-
bination with once daily tobramycin was both safe and effec-
tive. This adds additional information previously missing 
from the literature.
A few limitations of our study exist. This was a retrospec-
tive review, thus the sample size was small. SCr was used as 
a marker of renal function. SCr is affected by muscle mass 
and therefore can be quite variable in children with CF. 
Glomerular filtration rate (GFR) may have been a better 
measure; however, GFR is not routinely measured at our 
institution. eGFR was used in place of measured GFR. IV 
fluid use may have contributed to nephrotoxicity avoidance; 
however, these data were not collected. BUN/Cr ratio was 
used as a surrogate indicator of hydration status. Culture and 
susceptibility data were not recorded; however, the practice 
at our institution is to choose antibiotics based on available 
sputum cultures and susceptibility data.
Conclusion
In conclusion, ODD of IV tobramycin in combination with a 
variety of second anti-pseudomonal antibiotics, mainly 
piperacillin-tazobactam, did not cause nephrotoxicity in 
children with CF and led to notable physiologic improve-
ments in lung function. As the median age of survival of the 
CF population increases, delivery of IV antibiotic courses 
that are safe, effective, and decrease the risk of toxicity are 
important.
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